CoChat

Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.

Abstract

Purpose Transforming growth factor-beta inhibitors may enhance the antitumor activity of gemcitabine with acceptable safety and tolerability. This open-label, multicenter, non-randomized phase 1b study assessed the safety/tolerability, pharmacokinetics, and tumor response of galunisertib plus gemcitabine in Japanese patients with advanced or metastatic pancreatic cancer.Methods During each 28-day cycle, galunisertib 150 mg was administered orally twice daily (300 mg/day) for 14 days, followed by 14 days of rest. Gemcitabine 1000 mg/m 2 was intravenously given on Days 8, 15, and 22. Safety was assessed by the incidence of dose-limiting toxicities (DLTs) in the first cycle and treatment-emergent adverse events (TEAEs). Efficacy was assessed by antitumor activity and changes in carbohydrate antigen 19-9 (CA19-9).Results No DLTs were reported. All 7 enrolled patients had ≥1 TEAE, of which the most common included anorexia, decreased neutrophil count, and decreased white blood cell count. Grade ≥3 TEAEs were observed in 6 patients; 4 patients had Grade ≥3 TEAEs (decreased neutrophil, white blood cell, and lymphocyte count; hypophosphatemia) considered possibly related to study drug(s). The pharmacokinetic profile of galunisertib in combination with gemcitabine was similar to that previously observed for galunisertib alone. The clinical response [complete response (CR), partial response (PR), or stable disease] rate was 42.9%, and the median progression-free survival was 64 days; no CR/PR were achieved.Conclusion Galunisertib plus gemcitabine had an acceptable safety/tolerability profile with evidence of efficacy in Japanese patients with advanced or metastatic pancreatic cancer.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00280-017-3313-x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Schlingensiepen K-H, Stauder G, Bischof A, Egger T, Hafner M, Herrmuth H, Kielmanowicz M, Jachimczak P (2004) TGF-beta2 suppression in pancreatic cancer by the antisense oligonucleotide AP 12009: preclinical efficacy data. Proc Am Assoc Cancer Res 45(suppl):Abstract 2955

Cited by

See all 51

Metadata

Authors
Ikeda, M., Takahashi, H., Kondo, S., Lahn, M. M. F., Ogasawara, K., Benhadji, K. A., Fujii, H., & Ueno, H.
Affiliations
  • National Cancer Center Hospital East (JP)
  • National Cancer Center Hospital (JP)
  • Johns Hopkins University (US)
  • Eli Lilly (United States) (US)
  • Eli Lilly (Japan) (JP)
Corresponding author
Ikeda, Masafumi
Venue
Cancer Chemotherapy and Pharmacology
Published
2017-04-27
Volume
79
Issue
6
Pages
1169-1177
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2608573151
Cited by
51
References
14
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 6 · 2019: 10 · 2018: 6 · 2017: 1
FWCI
2.77
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company (US)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
galunisertib, gemcitabine, metastatic pancreatic cancer, locally advanced pancreatic cancer, TGF-β inhibitors, combination chemotherapy, safety and tolerability, pharmacokinetics, dose-limiting toxicity, CA19-9, Japanese patients
MeSH terms
Gemcitabine, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Pyrazoles, Quinolines, Biomarkers, Tumor, CA-19-9 Antigen, Disease-Free Survival, Area Under Curve, Maximum Tolerated Dose, Asian People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.